These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15975016)
1. Antibodies: can they protect against HIV infection? Mc Cann CM; Song RJ; Ruprecht RM Curr Drug Targets Infect Disord; 2005 Jun; 5(2):95-111. PubMed ID: 15975016 [TBL] [Abstract][Full Text] [Related]
2. Passive immunization as tool to identify protective HIV-1 Env epitopes. Kramer VG; Siddappa NB; Ruprecht RM Curr HIV Res; 2007 Nov; 5(6):642-55. PubMed ID: 18045119 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491 [TBL] [Abstract][Full Text] [Related]
4. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562 [TBL] [Abstract][Full Text] [Related]
5. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234 [TBL] [Abstract][Full Text] [Related]
6. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Ruprecht RM; Ferrantelli F; Kitabwalla M; Xu W; McClure HM Vaccine; 2003 Jul; 21(24):3370-3. PubMed ID: 12850342 [TBL] [Abstract][Full Text] [Related]
7. Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. Ferrantelli F; Rasmussen RA; Hofmann-Lehmann R; Xu W; McClure HM; Ruprecht RM Vaccine; 2002 Dec; 20 Suppl 4():A61-5. PubMed ID: 12477430 [TBL] [Abstract][Full Text] [Related]
8. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155 [TBL] [Abstract][Full Text] [Related]
11. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
12. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies against HIV -- back in the major leagues? Ferrantelli F; Ruprecht RM Curr Opin Immunol; 2002 Aug; 14(4):495-502. PubMed ID: 12088685 [TBL] [Abstract][Full Text] [Related]
14. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Ferrantelli F; Buckley KA; Rasmussen RA; Chalmers A; Wang T; Li PL; Williams AL; Hofmann-Lehmann R; Montefiori DC; Cavacini LA; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM Virology; 2007 Feb; 358(1):69-78. PubMed ID: 16996554 [TBL] [Abstract][Full Text] [Related]
15. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999 [TBL] [Abstract][Full Text] [Related]
16. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847 [TBL] [Abstract][Full Text] [Related]
17. Role of neutralizing antibodies in protective immunity against HIV. Srivastava IK; Ulmer JB; Barnett SW Hum Vaccin; 2005; 1(2):45-60. PubMed ID: 17038830 [TBL] [Abstract][Full Text] [Related]
18. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576 [TBL] [Abstract][Full Text] [Related]
19. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566 [TBL] [Abstract][Full Text] [Related]
20. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]